Janux Therapeutics Q2 EPS $(0.35) Beats $(0.38) Estimate, Sales $10.267M Miss $16.493M Estimate
Janux Therapeutics (NASDAQ:JANX) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0.38) by 7.89 percent. This is a 36.36 percent increase over losses of $(0.55) per share
Janux lost less money per share than experts thought, which is good, but the company made way less money overall than people expected. When a company misses on sales, it hints that customers might not be buying as much as hoped.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.